Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
DFA-02 Antibiotic · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| DFA-02 Antibiotic Gel | EXPERIMENTAL | Up to 20 mL of DFA-02 antibiotic gel will be placed in the surgical incision after closure of the fascia and before skin closure. |
| DFA-02 Placebo Gel | PLACEBO_COMPARATOR | Up to 20 mL of DFA-02 placebo gel will be placed in the surgical incision after closure of the fascia and before skin closure. |
| Standard of Care | NO_INTERVENTION | Prior to final closure of the surgical incision, the incision will be irrigated with normal saline and no gel will be applied. |
| Name | Type | Description |
|---|---|---|
| DFA-02 Antibiotic Gel | DRUG | - |
| DFA-02 Placebo Gel | DRUG | - |
Inclusion Criteria: 1. Males and females 18 years of age or older; 2. If female, the subject must be postmenopausal, surgically sterilized or, if of child-bearing potential, she must have a negative serum or urine pregnancy test within 48 hours of surgery and agree to use adequate birth control dur...
DFA-02 Antibiotic is an investigational small molecule being developed for the prevention of Surgical Site Infections. It is administered during abdominal surgery to reduce the risk of infection at the surgical site. The drug is currently in Phase 2 clinical development and is not yet approved by regulatory authorities.
DFA-02 Antibiotic is being developed by Dr. Reddy's Laboratories Ltd, a pharmaceutical company listed on the stock exchange under the ticker symbol RDY. The company is conducting clinical trials to evaluate the safety and efficacy of this investigational antibiotic for Surgical Site Infections.
DFA-02 Antibiotic is in Phase 2 clinical development. It is an investigational drug, meaning it has not been approved by regulatory agencies. The drug is being studied for its safety, efficacy, and tolerability in patients undergoing abdominal surgery to prevent Surgical Site Infections.
DFA-02 Antibiotic has one completed Phase 2 clinical trial registered as NCT01888367. This study evaluated the safety, efficacy, and tolerability of up to 20 mL of DFA-02 in 445 patients undergoing abdominal surgery in the United States. The trial was randomized, double-blind, and placebo-controlled.
DFA-02 Antibiotic is a small molecule antibiotic designed to prevent Surgical Site Infections. It is administered locally during abdominal surgery to target and eliminate bacteria at the surgical site, reducing the risk of postoperative infection. The specific molecular target of this drug has not been disclosed.
DFA-02 Antibiotic is a distinct investigational drug candidate developed by Dr. Reddy's Laboratories. No alternative names or brand names have been associated with this compound in the available clinical trial information. It is being studied specifically for the prevention of Surgical Site Infections.